fax: (33-4) 9977-69-12
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Original Article
You have full text access to this OnlineOpen article
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats†
Article first published online: 24 MAY 2007
DOI: 10.1002/hep.21641
Copyright © 2007 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Gary-Bobo, M., Elachouri, G., Gallas, J. F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., Arnone, M., Croci, T., Soubrié, P., Oury-Donat, F., Maffrand, J. P., Scatton, B., Lacheretz, F., Le Fur, G., Herbert, J. M. and Bensaid, M. (2007), Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology, 46: 122–129. doi: 10.1002/hep.21641
- †
Potential conflict of interest: Nothing to report.
Publication History
- Issue published online: 27 JUN 2007
- Article first published online: 24 MAY 2007
- Manuscript Accepted: 5 JAN 2007
- Manuscript Received: 30 AUG 2006
References
- 1. Patent focus on new anti-obesity agents: September 1999-February 2000. Expert Opin Ther Patents 2000; 10: 819–831.
- 2, . Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329–339.
- 3, . Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–355.
- 4. White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2005; 4: 637–647.
- 5, . Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765–3773.
- 6. The role of TNF alpha in insulin resistance. Endocrine 2004; 23: 177–182.
- 7, , . A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12: 180–186.
- 8, , , , . Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415.
- 9, , . Obesity, insulin resistance and cancer risk. Yonsei Med J 2005; 46: 449–455.
- 10, , , , . Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24: 644–649.
- 11, , . Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293: 455–462.
- 12. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595–2600.
- 13, . The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70–75.
- 14, , , , , , et al. Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance. J Clin Invest 2003; 112: 1821–1830.
- 15, , , , , . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–1737.
- 16, , , , , , et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975–981.
- 17
- 18, , , . Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303–306.
- 19
- 20, , , , , . The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91–100.
- 21, , . Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004; 53: 123–129.
- 22, , , , , , et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113–118.
- 23, , , , , , et al. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11: 1737–1741.
- 24, . Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439–451.
- 25, , . Adiponectin and cancer: a systematic review. Br J Cancer 2006; 94: 1221–1225.
- 26, , . Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764–2769.
- 27, , , , , , et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767–2770.
- 28, . Adiponectin: a novel adipokine linking adipocytes and vascular function. Clin Endocrinol Metab 2004; 89: 2563–2568.
- 29, , , , . Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004; 36: 165–173.
- 30, , , , , , et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004; 79: 502–509.
- 31, , , , , , et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415–424.
- 32, . Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467–1476.
- 33, , , , , , et al. Selective inhibition of sucrose and ethanol intake by SR 141716 an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997; 132: 104–106.
- 34, , , . Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998; 135: 324–332.
- 35, , , , , . Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: 113–117.
- 36, , , , , , et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822–825.
- 37, , , , , , et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2002; 284: R345–R353.
- 38, , , , , , et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.
- 39, , , , , , et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65–72.Direct Link:
- 40, , , , ; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.
- 41, , . Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.
- 42, , , , ; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761–775.
- 43. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003; 92: 35i–42i.
- 44, , . Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4–7.
- 45, , , , , . The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471–478.
- 46, . The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70–75.
- 47, , , , , , et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298–1305.
- 48, , . The endocannabinoid system and the treatment of obesity. Ann Med 2005; 37: 270–275.
- 49
- 50, , . Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci 2005; 330: 295–302.